- Agilent Technologies Launches Automated Electrophoresis System to Accelerate Sample and Library QC for Next-Generation Sequencing
Product News: Agilent Technologies Launches Automated Electrophoresis System to Accelerate Sample and Library QC for Next-Generation SequencingAgilent Technologies Inc. (NYSE: A) today launched the Agilent 2200 TapeStation to automate next-generation sequencing sample and library quality control. Together with the prepackaged, ready-to-use ScreenTape consumables, the 2200 TapeStation simplifies and accelerates quality control in the next-gen sequencing workflow.
“We are very excited about this launch,” said Patrick Kaltenbach, vice president of Agilent’s Liquid Phase Separations business. “The versatility of the TapeStation – not to mention the fact that ScreenTape consumables are ready to use and require only 2ul of sample for high sensitivity analysis – makes it the perfect tool for sample and library QC.”
Compatible with 16-tube strip vials and 96-well plates, the Agilent 2200 TapeStation is a fast and convenient automated benchtop system to measure the quality of biological samples. Customers simply load their samples and the ScreenTape consumable into the compact 2200 TapeStation instrument and in approximately one minute per sample, it displays fully analyzed results for protein, RNA and DNA samples.
“With its unique combination of automation, ease of use and scalable throughput, the TapeStation system is also ideally suited for sample quality control in gene expression, DNA fragment analysis and protein separation as well as next-generation sequencing in core research labs,” said Joel Fearnley, cofounder of Lab901, the originator of ScreenTape, which was acquired by Agilent earlier this year. “For applications like these, the TapeStation and ScreenTape deliver fast results, excellent reproducibility of data and constant cost per sample regardless of throughput.”
The new TapeStation and ScreenTape products complement Agilent´s electrophoresis portfolio, which includes the Agilent 2100 Bioanalyzer. The bioanalyzer is the first commercial instrument to use microfluidics for the analysis of biological samples, and is the market-leading device for RNA and DNA QC in microarray, qPCR and next-generation sequencing workflows.
Agilent also offers the market-leading SureSelect Target Enrichment System for next-gen sequencing, an in-solution hybrid capture technology first developed in collaboration with the Broad Institute of MIT and Harvard. Like the Agilent 2200TapeStation system, SureSelect also streamlines next-generation sequencing workflows. SureSelect enables researchers to sequence only genomic regions of interest.
For more information, visit the company article page